POLR2G inhibitors belong to a class of compounds that specifically target the POLR2G protein, a key component of the RNA polymerase II complex. RNA polymerase II is an essential enzyme responsible for transcribing DNA into messenger RNA (mRNA) during the process of transcription. POLR2G, one of the subunits of RNA polymerase II, plays a crucial role in the catalytic activity of the enzyme. The inhibitors designed to selectively modulate POLR2G function aim to interfere with the transcription process at its core, influencing gene expression and subsequent protein synthesis.
POLR2G inhibitors involves binding to the POLR2G subunit, disrupting its normal function and impeding the elongation phase of transcription. By inhibiting POLR2G, these compounds can potentially lead to the downregulation of specific genes, offering a tool for researchers to study gene expression patterns and unravel the intricate regulatory networks within cells. The development of POLR2G inhibitors represents a valuable contribution to the field of molecular biology, providing scientists with a means to explore the intricacies of transcriptional control and furthering our understanding of the molecular mechanisms governing gene expression. As researchers continue to investigate the specific effects and applications of POLR2G inhibitors, these compounds hold promise for uncovering new insights into the fundamental processes that govern cellular function and gene regulation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
α-Amanitin | 23109-05-9 | sc-202440 sc-202440A | 1 mg 5 mg | $269.00 $1050.00 | 26 | |
Binds directly to RNA polymerase II and prevents the elongation phase of RNA transcription. | ||||||
Triptolide | 38748-32-2 | sc-200122 sc-200122A | 1 mg 5 mg | $90.00 $204.00 | 13 | |
Binds to XPB, a subunit of TFIIH, leading to the inhibition of RNA polymerase II mediated transcription. | ||||||
DRB | 53-85-0 | sc-200581 sc-200581A sc-200581B sc-200581C | 10 mg 50 mg 100 mg 250 mg | $43.00 $189.00 $316.00 $663.00 | 6 | |
Inhibits transcription initiation and elongation by targeting RNA polymerase II. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $259.00 | 41 | |
Inhibits CDK9, a component of P-TEFb, which is necessary for phosphorylating the C-terminal domain of POLR2A. | ||||||
Cordycepin | 73-03-0 | sc-203902 | 10 mg | $101.00 | 5 | |
Termination of RNA chain elongation due to incorporation into RNA and subsequent chain termination. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
Interacts with DNA and prevents the RNA polymerase from continuing RNA synthesis. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
Proteasome inhibitor that can increase the half-life of proteins, potentially affecting POLR2G turnover. | ||||||
ICRF-193 | 21416-68-2 | sc-200889 sc-200889A | 1 mg 5 mg | $341.00 $927.00 | 7 | |
Inhibits DNA topoisomerase II, leading to an indirect effect on transcriptional regulation. | ||||||
CX-5461 | 1138549-36-6 | sc-507275 | 5 mg | $245.00 | ||
Inhibits RNA polymerase I, with indirect effects on overall transcriptional regulation. | ||||||